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Abstract
Neurofibromatosis (NF) is an inherited disease affecting multiple systems in 
the body. The eye is frequently affected in neurofibromatosis, and therefore ocular 
manifestations play a major role in the diagnosis of NF. This chapter aims to explore 
the spectrum of ocular manifestations found in neurofibromatosis highlighting the 
importance of ophthalmic exam in these patients. It will describe various intraocu-
lar manifestations involving the iris, lens, and retina. It will be focusing on glau-
coma and the pathogenesis behind it in this group of patients. Moreover, periorbital 
and orbital involvement such as skin neurofibromas and optic nerve gliomas will be 
discussed along with some of their histopathological findings.
Keywords: neurofibromatosis, glaucoma, cataract, retinal hamartoma, Lisch nodules, 
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1. Introduction
Neurofibromatosis (NF) is an inherited disease affecting multiple systems in 
the body. It is caused by a genetic mutation affecting cellular growth regulation, 
therefore resulting in disrupted pathways and formation of multiple tumors in the 
body. Ocular involvement is an important part of the disease as it may be required 
for the diagnosis. Although some manifestations are only of diagnostic value such 
as Lisch nodules, other ocular involvement can be vision threatening like glaucoma 
and optic nerve gliomas. Therefore, this chapter aims to explore how this disease 
can affect various structures of the eye and some histopathological changes that 
may be seen in some.
2. Types of neurofibromatosis
Neurofibromatosis is caused by a gene mutation affecting a tumor suppressor 
protein resulting in uncontrolled proliferation of neural cells that can involve vari-
ous parts of the body such as nerves, skin, and eyes. It is classified into two types 
based on the location of the mutated gene. Neurofibromatosis type 1 (NF-1), also 
known as von Recklinghausen disease, is caused by a mutation in the gene NF-1 
located on chromosome 17. This leads to a dysfunctional tumor suppressor protein 
known as neurofibromin. As a result, NF-1 manifests as multiple benign tumors in 
the body such as plexiform neurofibromas, Lisch nodules, and optic nerve gliomas. 
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NF-1 is inherited as autosomal dominant trait but may be sporadic in about 50% 
of the cases [1]. Ophthalmic manifestations are of diagnostic value in NF. Table 1 
shows the criteria that are used for the diagnosis of NF-1 [2]. Three out of the total 
seven may involve ocular structures. Therefore, an individual may be diagnosed 
with NF-1 solely on his ophthalmic exam.
Neurofibromatosis type 2 (NF-2) is caused by a chromosome 22 mutation in 
the gene encoding for the protein merlin or schwannomin, which is also a tumor 
suppressor protein. Dysregulation of this gene results in overproduction of 
Schwann cells. Therefore, the most prominent feature of this disease is bilateral 
vestibular schwannomas occurring in almost 90% of the patients. It may also 
affect different structures in the body causing tumors such as optic meningiomas 
and gliomas. Similar to NF-1, it is inherited in autosomal dominant fashion but 
may be sporadic [2].
Clinical presentation of both diseases may overlap as they both affect cellular 
growth of neural tissue. This chapter will be discussing ocular manifestations that 




Various intraocular conditions have been described in NF, most commonly, 
iris hamartomas. Iris hamartomas is a hallmark feature in NF-1 and is therefore 
considered one of the diagnostic criteria. Histologically, Lisch nodules have been 
described to be a collection of spindle cells that are melanocytic in origin [3]. They 
usually occur during childhood and increase in size and number with aging. They 
are typically seen under slit-lamp examination; are described as round elevated 
nodules within the iris, measuring around 2–3 mm in size; and are brown to yellow 
in color (Figure 1). Lisch nodules are typically bilateral; however, unilateral nodules 
have been reported previously in some types of NF [4].
3.2 Glaucoma
Glaucoma has been found to occur in about 1 in 300 NF-1 patients [5]. Patients 
with orbito-facial involvement have been linked to higher rates of glaucoma at 
23–50% [6–8]. It was also found that patients with eyelid plexiform neurofibromas 
have ipsilateral globe enlargement up to 36 mm axial length [6]. Although glaucoma 
Six or more café au lait macules (greatest diameter of >5 mm in prepubertal individuals and > 15 mm in 
postpubertal individuals)
Two or more neurofibromas of any type or one plexiform neurofibroma
Axillary or inguinal freckling.
Optic glioma
Two or more Lisch nodules (iris hamartomas)
A distinctive osseous lesion (sphenoid dysplasia or tibial pseudarthrosis)
A first degree relative with NF1
Table 1. 
Diagnostic criteria for NF1 (two or more must be present).
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in NF is not common, it has been studied due to the visual burden it may cause. 
Various mechanisms have been described in the pathogenesis of glaucoma in these 
patients. The most commonly described mechanism is the presence of neurofi-
bromas in the angle causing aqueous outflow obstruction [6]. Other suggested 
processes include secondary angle closure due to the anterior displacement of the 
peripheral iris by an abnormally thickened ciliary body or developmental anomalies 
in the angle [7].
Moreover, congenital ectropion uvea has been linked to refractory glaucoma in 
patients with NF. Histologically, endothelialization of the anterior chamber angle 
has been observed in these eyes. It has been hypothesized that loss of the NF gene 
and therefore RAS–RAF–ERK–MAPK pathway activation may be the cause of 
endothelial overgrowth in these patients [9]. It is difficult to link one mechanism 
causing glaucoma in NF as most cases are probably multifactorial as described 
above.
3.3 Lens
Lens opacities are of importance in NF-2 as they may be the first sign to suggest the 
diagnosis during childhood [10]. NF-2 typically causes posterior subcapsular cataract 
or cortical cataract and occurs in 60–80% of patients with the disease [10, 11].
3.4 Retina and choroid
Retinal astrocytic hamartomas are benign tumors that usually affect the optic 
nerve. They clinically resemble a small white mulberry and are mostly linked to 
tuberous sclerosis but have been reported in NF patients as well. Rarely, those 
lesions may extend to the peripheral retina and cause devastating complications 
such as neovascular glaucoma and retinal detachment. Other retinal lesions 
described in NF patients include combined hamartoma of the retina and retinal 
pigment epithelium (CHR-RPE) and retinal capillary hemangiomatosis [12–14].
In the past, choroidal involvement was thought to be uncommon in NF patients 
as it was difficult to visualize subtle changes with fundus examination and conven-
tional angiography. However, with the development of new diagnostic technologies 
such as optical coherence tomography (OCT), choroidal changes have been found 
to reach up to 100% of NF patients [15]. Uveal neurofibromatosis has been also 
demonstrated histopathologically within the choroid (Figure 2) [9].
Figure 1. 
Slit-lamp photo of an iris showing Lisch nodules in a patient diagnosed with neurofibromatosis.
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4. Periocular and orbital manifestations
4.1 Optic pathway glioma
Optic pathway gliomas are low-grade tumors which are classified as WHO grade 
I pilocytic astrocytomas. They usually occur early in childhood in around 5–25% of 
NF patients [15]. Although benign, these tumors can cause significant visual loss 
due to the direct compression of the optic nerve. They may arise anywhere along the 
optic pathway from the optic nerve to the chiasm and radiation. When those tumors 
involve the orbit, they may cause unilateral proptosis, strabismus, and decreased 
vision. Due to the nature of these tumors and the catastrophic consequences they 
may have, annual screening for all NF patients less than 10 years of age and then 
every 2 years until the age of 18 years is recommended [16].
4.2 Orbital-periorbital plexiform neurofibroma (OPPN)
One of the most characteristic findings in NF-1 patients and a hallmark of 
the disease is plexiform neurofibroma. It is a congenital tumor usually unilateral 
involving the eyelid, orbit, and periorbital area. It starts early in childhood with 
rapid growth that slows down after puberty. OPPN affects approximately 10% of 
patients with NF-1, and it carries a risk for malignant transformation in about 10%. 
It is considered a benign tumor of peripheral nerves with spindle cell proliferation 
and wavy filamentous pattern of growth (Figures 3 and 4). Histologically, they may 
be composed of mixed diffuse and plexiform types (Figure 5) with proliferation 
of Schwann cells, fibroblasts, and mast cells. Plexiform neurofibromas are similar 
but are encapsulated with the proliferations being surrounded by perineurium 
(Figure 6). Plexiform neurofibromas are of clinical significance as they are often 
described clinically as a “bag of worms” and can grow to form bulging masses that 
can be quiet disfiguring to a patient leading to social embarrassment. They usually 
cause mechanical ptosis when involving the upper eyelid (Figure 7), which may 
lead to amblyopia in children. Further progression to orbital and periorbital areas 
lead to proptosis, strabismus, and displacement of the globe. Rarely, plexiform 
neurofibromas may also involve the conjunctiva of the eye. Sphenoid wing dysplasia 
can be found in patients with OPPN affecting the same side and usually present 
with proptosis and pulsatile exophthalmos. Plexiform neurofibroma is a highly 
recurrent tumor, especially in orbito-facial area and in younger patients [17–19].
Figure 2. 
The choroid in a neurofibroma patient with spindle and ganglion cells (original magnification X400 
hematoxylin and eosin).
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Figure 3. 
Neurofibroma of the diffuse type with spindle cell proliferation (original magnification X400 
hematoxylin and eosin).
Figure 4. 
The same diffuse type of neurofibroma with spindle cells expressing s-100 staining (original 
magnification X200 S-100).
Figure 5. 
Mixed plexiform (black star) and diffuse (red arrowhead) neurofibromatosis (original 
magnification X100 hematoxylin and eosin).
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5. Imaging
A high-resolution magnetic resonance imaging (MRI) with and without contrast 
of the brain and orbits should be performed in all NF-suspected patients to con-
firm the diagnosis and to monitor for the progression. CT scan should be avoided 
if possible, because of its radiation and the risk of malignant transformation of 
neurofibroma [19].
6. Management
Patients with NF need a multidisciplinary team of pediatric ophthalmology, 
neuro-ophthalmology, oculoplastic surgeon, neuro-oncology, and genetics. All chil-
dren diagnosed with NF should have regular ophthalmological examinations every 
6 months until the age of visual maturation (7 years) to detect and treat amblyopia, 
glaucoma, or strabismus. Also, serial MRI might be needed. The frequency of 
examination and imaging should be tailored according to the patient needs and 
disease progression. Early diagnosis and management of ophthalmic related issues 
are important and usually treated by supportive methods.
In children, surgical interventions for neurofibroma and its related strabismus 
should be reserved for severe cosmesis and visually threatening conditions because 
of its highly recurrent nature. Adults with neurofibroma usually need an aggres-
sive and definitive surgical approach to prevent recurrence with the possibility of 
Figure 7. 
A child with a plexiform neurofibroma of the right upper eyelid causing significant ptosis that 
affects the visual axis.
Figure 6. 
An area of typical plexiform neurofibroma (original magnification X100 hematoxylin and eosin).
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several surgeries. The most common indications for surgical debulking are cos-
metic, decreased vision, progressive involvement of a vital structure, and func-
tional deficits. Any significant increase in the growth rate of neurofibroma that is 
unusual for the patient age should be worrisome for malignant transformation [19].
7. Conclusion
In conclusion, neurofibromatosis can affect the eye and ocular adnexa in various 
ways. It is of importance to recognize ocular involvement in such patients in order 
to help earlier diagnosis of treatable conditions that can be vision-threatening.
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